Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Furniture Press Releases.
Press releases published on May 14, 2025
Long-Serving Director Alan J. Murray Retiring; Eugenio Garza y Garza and Iain J. Mackay Elected to O-I Board of Directors
GlobeNewswire
·
May 14, 2025
PERRYSBURG, Ohio, May 14, 2025 (GLOBE NEWSWIRE) -- -- O-I Glass, Inc. (“O-I” or the “Company”) (NYSE: OI) today announced, after the conclusion of O-I’s Annual Meeting of Share Owners held earlier today, that Alan J. Murray is retiring from O-I’s Board of …
HP Inc. Declares Dividend
GlobeNewswire
·
May 14, 2025
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) has declared a cash dividend of $0.2894 per share on the company’s common stock. The dividend, the third in HP’s fiscal year 2025, is payable on July 2, 2025, to stockholders of record …
Navigator Gas Announces Preliminary First Quarter 2025 Results (Unaudited)
GlobeNewswire
·
May 14, 2025
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- First Quarter Financial Highlights On May 14, 2025, the Board of Navigator Holdings Ltd., (NYSE: NVGS) (“Navigator Holdings,” "Navigator Gas," “our,” “we,” “us” or the “Company”) declared a cash dividend of $0.05 …
Northrop Grumman to Host Virtual Annual Shareholders Meeting
GlobeNewswire
·
May 14, 2025
FALLS CHURCH, Va., May 14, 2025 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will conduct its annual shareholders meeting exclusively online on Wednesday, May 21 at 8 a.m. Eastern time. You may access the virtual meeting by following this …
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
GlobeNewswire
·
May 14, 2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …
USA Rare Earth Reports its First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
STILLWATER, Okla., May 14, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (“USAR” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025. First Quarter Highlights Merged with Inflection Point and …
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
GlobeNewswire
·
May 14, 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity …
Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2025 Results
GlobeNewswire
·
May 14, 2025
ROSEVILLE, Minn., May 14, 2025 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) today announced fourth quarter and full-year results for its fiscal year ended March 30, 2025. Fourth Quarter Fiscal Year 2025 Highlights: Record fourth quarter sales of $245.3 …
Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination
GlobeNewswire
·
May 14, 2025
WILMINGTON, Del., May 14, 2025 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline …
Castor Maritime Inc. Announces Availability of its 2024 Annual Report on Form 20-F
GlobeNewswire
·
May 14, 2025
LIMASSOL, Cyprus, May 14, 2025 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM), (“Castor”, or the “Company”), a diversified global shipping and energy company, announces that the Company’s annual report on Form 20‐F (the “Annual Report”), which …
Aterian Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 14, 2025
SUMMIT, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). The Company also provided an …
Shimmick Corporation Announces First Quarter 2025 Results
GlobeNewswire
·
May 14, 2025
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, climate resilience, energy transition and sustainable transportation, today announced financial results for the first …
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 14, 2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential …
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
May 14, 2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
May 14, 2025
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …